Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate
- PMID: 30368666
- PMCID: PMC6325989
- DOI: 10.1007/s00432-018-2779-1
Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate
Abstract
Purpose: Mutated KRAS oncogene in exhaled breath condensate (EBC) can be a genetic marker of non-small cell lung cancer (NSCLC). However, a possibility of inhomogeneous distribution in cancer tissue and intratumor heterogeneity of KRAS mutation may decrease its significance. We investigated a status of KRAS point mutation and its sequence at codon 12 in 51 NSCLC patients after tumor resection. The comparison of KRAS mutation status between EBC-DNA and cancer tissue was performed in 19 cases.
Methods: Five cancer tissue samples from disparate tumor regions and one from normal lung were harvested at surgery. EBC was collected for DNA analysis the previous day. KRAS point mutations at codon 12 were detected using mutant-enriched PCR technique and pyrosequenced.
Results: Forty-six cancers revealed concordance of KRAS mutation status: 27 contained mutated KRAS and 19 had only wild KRAS. Five NSCLCs revealed inhomogeneous distribution of KRAS mutation. Two different mutations were found in 14 NSCLCs and the most frequent one was G12D and G12V (n = 8). No mutated KRAS was found in normal lung. The concordance ratios of KRAS sequence in codon 12 between EBC-DNA and cancer were 18/19 for NSCLC patients and 11/12 for KRAS mutation positive NSCLC.
Conclusions: Intratumor heterogeneity and inhomogeneous distribution of KRAS point mutation in codon 12 in cancer tissue can occur in NSCLCs. There was a high accordance between KRAS mutation status in EBC-DNA and cancer tissue in NSCLC patients what suggests usefulness of monitoring KRAS mutation in EBC-DNA as a biomarker of NSCLC.
Keywords: Exhaled breath condensate; Genetic biomarkers; Heterogeneity; KRAS oncogene mutation; Non-small cell lung cancer.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures

Similar articles
-
Complete surgical resection of lung tumor decreases exhalation of mutated KRAS oncogene.Respir Med. 2012 Sep;106(9):1293-300. doi: 10.1016/j.rmed.2012.06.019. Epub 2012 Jul 13. Respir Med. 2012. PMID: 22795503
-
Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients.Lung Cancer. 2004 Feb;43(2):215-22. doi: 10.1016/j.lungcan.2003.08.034. Lung Cancer. 2004. PMID: 14739043 Clinical Trial.
-
Concordance in molecular genetic analysis of tumour tissue, plasma, and exhaled breath condensate samples from lung cancer patients.J Breath Res. 2020 Apr 15;14(3):036001. doi: 10.1088/1752-7163/ab739b. J Breath Res. 2020. PMID: 32031993
-
DNA variants detected in primary and metastatic lung adenocarcinoma: a case report and review of the literature.Lab Med. 2024 Sep 4;55(5):658-662. doi: 10.1093/labmed/lmae019. Lab Med. 2024. PMID: 38527227 Free PMC article. Review.
-
Exhaled breath analysis for lung cancer.J Thorac Dis. 2013 Oct;5 Suppl 5(Suppl 5):S540-50. doi: 10.3978/j.issn.2072-1439.2013.08.44. J Thorac Dis. 2013. PMID: 24163746 Free PMC article. Review.
Cited by
-
Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis.Small GTPases. 2022 Jan;13(1):114-127. doi: 10.1080/21541248.2021.1906621. Epub 2021 May 5. Small GTPases. 2022. PMID: 33949915 Free PMC article.
-
Targeting KRAS: The Elephant in the Room of Epithelial Cancers.Front Oncol. 2021 Mar 11;11:638360. doi: 10.3389/fonc.2021.638360. eCollection 2021. Front Oncol. 2021. PMID: 33777798 Free PMC article. Review.
-
KRAS G12C Mutations in NSCLC: From Target to Resistance.Cancers (Basel). 2021 May 21;13(11):2541. doi: 10.3390/cancers13112541. Cancers (Basel). 2021. PMID: 34064232 Free PMC article. Review.
-
Non-Invasive Biomarkers for Early Lung Cancer Detection.Cancers (Basel). 2022 Nov 24;14(23):5782. doi: 10.3390/cancers14235782. Cancers (Basel). 2022. PMID: 36497263 Free PMC article. Review.
-
An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer.Lung Cancer (Auckl). 2021 Aug 16;12:81-92. doi: 10.2147/LCTT.S320493. eCollection 2021. Lung Cancer (Auckl). 2021. PMID: 34429674 Free PMC article. Review.
References
-
- Alsdorf WH, Clauditz TS, Hoenig T, Quaas A, Sirma H, Koenig AM, Izbicki J, Sauter G, Marx AH, Grob TJ (2013) Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer. Exp Mol Pathol 94:155–159 - PubMed
-
- Benesova L, Minarik M, Jancarikova D, Belsanova B, Pesek M (2010) Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Res 30:1667–1671 - PubMed
-
- Carpagnano GE, Palladino GP, Gramiccioni C, Foschino Barbaro MP, Martinelli D (2010) Exhaled ERCC-1 and ERCC-2 microsatellite alterations in NSCLC patients. Lung Cancer 68:305–307 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous